Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0016053 (
fibromyalgia
)
4,687
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Fibromyalgia syndrome
(
FMS
) is a central sensitization syndrome; however, peripheral pain sources potentially exacerbate its symptoms of chronic diffuse musculoskeletal pain and hyperalgesia. This prospective study evaluated visceral pain as a possible triggering factor for
FMS
pain and hyperalgesia in comorbid patients. Women with (1)
FMS
+ irritable bowel syndrome (IBS); (2)
FMS
+ primary dysmenorrhea (Dys); (3)
FMS
+ Dys secondary to endometriosis (Endo); (4)
FMS
+ colon
diverticulosis
(Div) were compared with
FMS
-only women, for
fibromyalgia
pain (number and intensity of episodes and analgesic consumption) over comparable periods and for somatic hyperalgesia (electrical and pressure pain thresholds) in painful (tender points) and control areas (trapezius, deltoid, quadriceps muscles, and overlying subcutis and skin). In comorbid subgroups,
FMS
symptoms were also reassessed after treatment of the visceral condition or no treatment. All comorbid groups vs
FMS
-only had significantly higher
FMS
pain (number/intensity of episodes and analgesic consumption) and hyperalgesia in deep somatic tissues (subcutis and muscle) at all sites (0.05 < P < 0.0001). Visceral pain (number of IBS days, painful menstrual cycles, and abdominal pain episodes from diverticulitis) correlated directly with all parameters of
FMS
pain and inversely with muscle pain thresholds at all sites (0.03 < P < 0.0001).
Fibromyalgia syndrome
pain and hyperalgesia in all tissues and all sites significantly decreased in patients after visceral comorbidity treatment (dietary for 6 months [IBS], hormonal for 6 months [dysmenorrhea], laser [endometriosis], and surgery [
diverticulosis
]) (0.05 < P < 0.0001) vs no change in untreated patients. Visceral pain enhances
FMS
symptoms, probably augmenting the level of central sensitization typical of the syndrome. Systematic assessment and treatment of visceral pain comorbidities should be a part of
FMS
management strategy.
...
PMID:Visceral pain as a triggering factor for fibromyalgia symptoms in comorbid patients. 2868 25